Leg, Foot Amputations Linked To Invokana Being Investigated By FDA, Europe
The FDA said the interim safety results are from the Canagliflozin Cardiovascular Assessment Study (CANVAS) clinical trial. It said the trial’s independent data-monitoring committee identified the increased risk of leg and foot amputations.
“The amputations occurred about twice as often in patients treated with canagliflozin...
To view the full article, register now.